Tuesday, July 3, 2012

Living With Als

Maryland Retirement Communities - Living With Als The content is good quality and helpful content, Which is new is that you simply never knew before that I know is that I have discovered. Before the unique. It's now near to enter destination Living With Als. And the content related to Maryland Retirement Communities. Advertisements

Do you know about - Living With Als

Maryland Retirement Communities! Again, for I know. Ready to share new things that are useful. You and your friends.

Hello, my name is Buddy Sowell and I have Als (Lou Gehrig's Disease). In September 2007 I visited a Neurologist to get some answers as to why my muscles were persistently twitching. I had some muscle cramping & dinky fatigue, but thought nothing of it. After some seemingly useless muscle vigor testing, Dr Dooley looked at me with confident concern on his face. I thought it was maybe the fact that he was in his upper 80s and he all the time looked that way...anyway, he recommend that I see a Neurology scholar named Dr. Robert Baloh at Washington University curative Center. After some intense and painful testing and months of excruciating waiting... I was surprisingly diagnosed with Als. "You've got to be kidding" I remember saying...

What I said. It isn't outcome that the actual about Maryland Retirement Communities. You check this out article for home elevators a person wish to know is Maryland Retirement Communities.

How is Living With Als

We had a good read. For the benefit of yourself. Be sure to read to the end. I want you to get good knowledge from Maryland Retirement Communities.

Never in a million years would I have guessed that something like this would have happened to me and to my family. My wife Lori and my daughters Carly and Casey are my whole world. I love them more than words can describe. They have all made me a best person. My analysis is uncertain, but I will fight. My loving family doesn't deserve this...so I fight for them.

Lori and I talked canididly about what we should do next. We decided to take benefit of what time we still have together and focus on having fun as a family. No more putting off tour plans. Let's try to do as much as we can right now. I know population who have a "live for today" mentality, and I truly believe that we should all supervene that philosophy. Never turn down a occasion to have fun.

My dilemma: How do I tell my friends and family? Do I wait for the health to worsen, or get the word out now and get the introductory shock over with? I look normal, so maybe now would be a best option before I'm in a wheel chair or look sickly. I don't want anything to look at me differently. I don't want any special concentration and I verily don't want anything to feel sorry for me. (Thanks for those few who knew about me earlier and didn't mention it.)

One of my fears is that man will get the idea to offer up a special intention for me at church...and I'll gradually sink into the pew. I appreciate the thoughts and prayers, but please don't do that. I'll find a way to get you back...

Seriously, my option is to tell population as I see them or make contact by email. Since I don't get out much, email seems the easiest way.

Now, on a more confident note, Dr. Baloh's Lab has made advance in converting skin stem cells into nerve cells in mice. I know I'm not a mouse, but it's a huge step. Once this science is supplementary along, nerve cells (from stem cells) can be utilized to replace damaged nerve cells and hopefully find a cure for Als and many other neurological diseases.

Just what is Als? (Amyotrophic Lateral Sclerosis) is a motor neuron disease, first described in 1869 by the noted French neurologist Jean-Martin Charcot. Although the cause is not completely understood, the last decade has brought a wealth of new scientific understanding about the disease that provides hope for the future.

Lou Gehrig first brought national and international concentration to the disease in 1939 when he right away retired from baseball after being diagnosed with Als. Most commonly, the disease strikes population in the middle of the ages of 40 and 70, and as many as 30,000 Americans have the disease at any given time. This disease has cut short the lives of other such supreme and courageous individuals as Hall of Fame pitcher Jim "Catfish" Hunter, Senator Jacob Javits, actors Michael Zaslow and David Niven, originator of Sesame road Jon Stone, television producer Scott Brazil, boxing champion Ezzard Charles, Nba Hall of Fame basketball player George Yardley, pro football player Glenn Montgomery, golfer Jeff Julian, golf caddie Bruce Edwards, British soccer player Jimmy Johnstone, musician Lead Belly (Huddie Ledbetter), photographer Eddie Adams, entertainer Dennis Day, jazz musician Charles Mingus, composer Dimitri Shostakovich, former vice president of the United States Henry A. Wallace and U.S. Army normal Maxwell Taylor.

Als is a neurodegenerative disease that regularly attacks both upper and lower motor neurons and causes degeneration throughout the brain and spinal cord. A base first symptom is a painless infirmity in a hand, foot, arm or leg, which occurs in more than half of all cases. Other early symptoms contain speech swallowing or walking difficulty. The biological mechanisms that cause Als are only partially understood. The only known cause of Als is a mutation of a definite gene: the Sod1 gene. This mutation is believed to make a defective protein that is toxic to motor nerve cells. The Sod1 mutation, however, accounts for only 1 or 2 percent of Als cases, or 20 percent of the familial (inherited) cases. Familial Als represents in the middle of five to 10 percent of all cases. The rest arise spontaneously and mysteriously, production seemingly random attacks on previously wholesome adults. Als can assault anyone, anytime.

Physicians have dinky choices for treating Als, and the options that do exist have come into use within the last 10 years. Studies advise that patients' distance of survival and potential of life are enhanced by night-time breathing aid early in the course of the disease and by aggressive application of alternate feeding options to assure good nutrition once swallowing becomes difficult. At this time, riluzole is the only drug that has been popular ,favorite by the Fda for medicine of Als. In clinical trials, riluzole has shown a dinky benefit in modestly increasing survival time.

Stem cell and gene therapy are promising areas of research. In a range of studies, Als mouse models are being used to compose treatments that may someday lead to similar human clinical trials. Gene therapy is one field of research where The Als connection is concentrating maintain for more study. If you would like to send a donation click here.

More essential advances of research into Als has occurred in the last decade than all of the time since Charcot identified the disease. Advances in technology and the genetic revolution are aiding researchers in unlocking the Als mystery. As more scientists focus on this perplexing disease, the outlook for new understanding brightens each day.

What Are Stem Cells?

Stem cells, also known as progenitor cells, are cells that have not undergone differentiation to get a definite buildings or role; they have the inherent to self-renew, divide, and differentiate into specialized cell types. They are also sometimes termed "pluripotential" or "undifferentiated" cells because they can differentiate and compose into discrete cell lines. The differentiation of stem cells into mature cells is tightly regulated; otherwise, intricate plants and animals, with their many interrelated tissues, organs, and systems, could not exist.

By contrast, mature or differentiated cells have acquired definite structures and roles, and in many cases have lost the potential to divide and replicate. Also in dissimilarity to stem cells, malignant cells or "dedifferentiated" cells divide in an uncontrolled fashion, and rather than resulting in useful, differentiated, or specialized cells, these types of cells threaten to kill the organism.

Stem cell differentiation must be turned on, given direction, and turned off as needed in order to properly provide the basic building blocks of tissues in dissimilar organ systems. This requirement for correct regulation applies to an even greater degree to the differentiation of neuronal progenitor cells, because effective neural function depends on establishing correct linkages and interactions in the middle of dissimilar individual neurons and classes of neurons.

By definition, stem cells, including neuronal progenitor cells, are gift in embryos. Stem cells may be found in umbilical cord blood. In adults, these cells are gift in bone marrow and in other organs in which controlled self-renewal is needed. Neuronal progenitor cells have also been shown to persist into adulthood in definite brain locations near the ventricles where they maintain ongoing studying and the preparation of new memories straight through their division, differentiation, migration, and insertion into new circuitry.

Is There a Role for Stem Cell Therapy? Stem cells could help patients with Als in several ways. Ideally, they could be induced to differentiate into lower motor neurons in order to replace those neurons that die because of Als. Perhaps stem cells could rescue dying motor neurons by reconnecting these neurons to partly denervated muscle before it has died completely. best yet, they could be induced to differentiate into upper motor neurons in the cortex and join together to the lower motor neurons.

Unfortunately, the hope that stem cells will play such a regenerative role in patients with Lou Gehrig's disease is unrealistic because of the complexity of the task, which presents obstacles that currently are insurmountable. A more realistic hope for stem cells is that they play a supportive role in maintaining the viability of or extending the function of surviving motor neurons. The stem cells could be induced to differentiate into supporting cells, glia, or interneurons that might yield factors that would maintain motor neurons, or Perhaps the stem cells themselves might yield such factors.

What Do Existing Data Suggest?

Recent data from Clement and colleagues show that in chimeric, genetically engineered mouse models, motor neurons carry mutated Sod1 genes and glial cells carry wholesome genes. Survival is extended in these chimeric mice, as compared with nonchimeric mice in which all motor neurons and all glial cells carry mutated Sod1 genes. This finding suggests that if wholesome stem cells could get to the spinal cords of patients with Als, their survival might also be extended. It remains to be determined whether a mechanism that compensates for a particular genetic error would apply to sporadic patients without that error. Nevertheless, even if this form of therapy were effective only for patients with familial disease, it would be a great leap forward.

In former experiments, intraspinal transplantation of neurons derived from a human teratoma cell line was shown to ameliorate dysfunction and enlarge survival in G93A Sod1 transgenic mice. Furthermore, the life span of G93A Sod1 mice was extended by intravenous supervision of human umbilical cord blood. The cells were shown to have migrated into the spinal cord and brain parenchyma and survived 10-12 weeks after infusion. They exerted their useful supervene even though only a low number of transplanted cells expressed neural antigens. In an additional one study, Sertoli cells, which are not neuronal stem cells, were implanted in the spinal cords of Sod1 transgenic mice and were shown to provide temporary security to motor neurons in their proximity. However, viable Sertoli cells were not gift at the time when the animals died.

Preliminary trials with autologous hematopoietic stem cells have been reported in humans. In one, peripheral blood-purified Cd34+ cells were injected intrathecally into 3 patients with Als. None reported side effects after 6-12 months, but no clinical efficacy was reported. In another, 7 patients received intraspinal transplantation of autologous bone marrow-derived stem cells. Minor postoperative adverse events were transient, but muscle vigor continued to decline. After 3 months, however, the investigators reported a trend toward slowing of the decline in the proximal muscle groups of the lower limb in 4 patients and a mild growth in vigor in 2 patients. Lack of placebo controls and longer follow-up forestall any inferences of efficacy from this study and none were made by the investigators.

Stem Cell Research: Ethics, Economics, Policy, and public Health

The ethics of performing human studies at this early stage of stem cell research have been questioned, emphasizing the risks of premature human trials. Reports of stem cell transplantation performed in China without peer quote of objective data on each inpatient before, immediately after, and at definite long-term points following the transplantation do not provide adequate scientific evidence to demonstrate that the medicine is safe and effective.

"It is essential that scientists and clinicians are cautious, plan careful studies, and most importantly focus on key laboratory experiments that will provide answers to the many challenges that still face this therapeutic approach," wrote Lucie Bruijn, PhD, the Science Director and Vice President of the Als Association. "For this therapy to be safe and have inherent in the clinic, it is essential that the standard studies are conducted to learn more about the properties and complexities of the discrete stem cells."

In response to limitations on the type of stem cell research that may be performed with federal funds, the American Academy of Neurology and the American Neurological connection -- the 2 foremost professional neurology organizations in the United States -- have both gone on report expressing the belief that both embryonic and adult stem cell research should be pursued rigorously and under close scrutiny, while respecting the concerns of their members and the public, with regard to foremost ethical law and values pertaining to research with human embryonic stem cells.

The scientific concerns are 2-fold. First, because the realistic likelihood for success of any individual research endeavor is low, parallel research in complicated directions is imperative for the field to advance rapidly. The essence of research is trial and error, which operates by identifying ineffective directions and thereby focusing on those that hold promise. It is regularly a long time in the middle of initiating research and realizing a thriving medicine with clinical applications. Therefore, any delay in identification of a potentially effective therapeutic intervention translates into delaying treatments for patients with the diseases in question. Second, excluding particular types of research from federal funding may translate into an exclusion of this research from federal oversight and protections, which might lead to its migration overseas. This may be detrimental to individual patients and to the broader community of patients, clinicians, and scientists.

In November 2004, California citizens popular ,favorite a referendum quantum to issue bonds to fund stem cell research, including embryonic stem cell research at 0 million a year for 10 years. Since then, several other states (Illinois, New Jersey, Maryland, New York, Delaware, and Wisconsin) are considering, or being asked to consider, initiatives for state-funded stem cell research to fill the federal funding gap. This is motivated, in part, by the desire to remain on the forefront of curative research and avert a brain drain toward states that provide an economic environment more conducive to cutting-edge research. The ripple supervene of the California initiative is unbelievable to supervene in acceleration of stem cell research nationwide.

Conclusion

Stem cell research carries promise for patients with Als and may supervene in the amelioration of new treatments to slow the progression of the disease. This hope needs to be tempered with caution because of the early stages of stem cell research in general, and in Als in particular, and because of the track report of the dinky efficacy of all pharmacologic interventions in transgenic murine and sporadic human Als. careful concentration to the ethics and scientific rigor of future stem cell research should be supported by clinicians, scientists, and participating patients alike.

I hope you receive new knowledge about Maryland Retirement Communities. Where you can offer easy use in your everyday life. And most importantly, your reaction is Maryland Retirement Communities.Read more.. Living With Als. View Related articles associated with Maryland Retirement Communities. I Roll below. I have suggested my friends to assist share the Facebook Twitter Like Tweet. Can you share Living With Als.


No comments:

Post a Comment